Please login to the form below

Not currently logged in
Email:
Password:

gastric cancer

This page shows the latest gastric cancer news and features for those working in and with pharma, biotech and healthcare.

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

While there remains an unmet need for heavily pre-treated patients with advanced gastric cancer, we recognise that the treatment landscape has evolved and we respect the FDA’s efforts to ... Our research with Keytruda has contributed to recent advances

Latest news

More from news
Approximately 6 fully matching, plus 78 partially matching documents found.

Latest Intelligence

  • BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches

    the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell lung cancer, PSMA in prostate cancer and CLDN18.2 and MUC17 in gastric or ... T cells only become activated and proliferate, with the goal of staying

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Other important read-outs in first-line kidney, oesophageal and gastric cancer are also due this year, as well as adjuvant (post-surgery) trial results later this year and in 2021. ... If successful, that would dramatically increase the eligible patient

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... The field is marching on rapidly. Studies of checkpoint inhibitors are now taking place in less common forms of cancer with greater

  • Astellas: Ten years young Astellas: Ten years young

    There it is currently conducting a series of investigations in breast cancer to assess Xtandi's potential. ... It's not all been plain sailing for Astellas in oncology - a couple of candidates, notably rilotumumab, have fallen by the wayside in gastric

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214. ... 525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast /   gastric

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...